NCT06327178招募中不适用
Response to the Combination of Stereotactic Body Radiation Therapy and Concurrent PD-1 Blockade in Patients With Metastatic Renal Cell Carcinoma: a Retrospective Study
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 20
- 试验地点
- 1
- 主要终点
- Objective Response Rate
研究概览
简要总结
Prior research has indicated that stereotactic body radiotherapy (SBRT) can effectively trigger systemic anti-tumor immune response. The goal of this observational study is to learn about abscopal effects of stereotactic body radiotherapy and concurrent anti-PD-1 antibody treatment in patients of metastatic clear renal cell carcinoma. The primary objective was to assess the objective response rate (ORR) in non-irradiated lesions, and incidence of adverse events (AEs).
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age≥18 years at the time of signing informed consent;
- •Histologically confirmed, advanced renal cell carcinoma of stage IV (AJCC 8);
- •Previously received SBRT and concurrent PD-1 blockade treatment；
- •Evidence of measurable metastatic kidney cancer according to RECIST 1.1 criteria.
排除标准
- •Patients who cannot be adequately followed up;
- •Has a known additional malignancy that is progressing or requires active treatment.
结局指标
主要结局
Objective Response Rate
时间窗: Up to 2 years.
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
终止
不适用
Stereotactic Radiation Therapy and Sorafenib in the Treatment of Hepatocellular CarcinomaHepatocellular CarcinomaLiver CancerNCT01005875University of Alabama at Birmingham5
Unknown
2 期
SBRT Compared With IMRT Concurrently With Chemotherapy in Treating Patients With LS-SCLCSmall Cell Lung CancerNCT02738723Third Military Medical University50
撤回
不适用
Stereotactic Body Radiotherapy for Lung Lesions With Markerless Tracking (MLT) on the VERO® SBRT SystemStereotactic Body RadiotherapyLung DiseasesLung Cancer MetastaticLung Cancer Stage IVLung Cancer, Nonsmall CellLung CancerNCT06722885Universitair Ziekenhuis Brussel
进行中（未招募）
2 期
SBRT Followed by Neoadjuvant Immunochemotherapy in Resectable Stage II to III Non-small Cell Lung CancerCarcinoma, Non-Small-Cell LungNCT05319574Sun Yat-sen University46
进行中（未招募）
不适用
Stereotactic Body Radiotherapy (SBRT) for Medically Inoperable Localised Renal Tumors (SABINA Trial)Kidney NeoplasmRenal CancerInoperable DiseaseSBRTSABRNCT05817604Consorci Sanitari de Terrassa60